Literature DB >> 16617566

Expression of IL-10 in patients with ovarian carcinoma.

Alexander Mustea1, Dominique Könsgen, Elena Ioana Braicu, Cristina Pirvulescu, Pengming Sun, Dumitru Sofroni, Werner Lichtenegger, Jalid Sehouli.   

Abstract

BACKGROUND: Cytokines are involved in the pathogenesis of different gynecological malignancies. Additionally, they stimulate the spread of cancer cells. Interleukin 10 (IL-10) was described as a pro-inflammatory factor and seems to be implicated in the immune deficiency of patients with cancer. The aim of this study was to determine whether the level of IL-10 in the serum and ascites was associated with the prognosis of advanced ovarian cancer (OC).
MATERIALS AND METHODS: In a prospective study from 2001 to 2003, the concentration of IL-10 in the serum and ascites of 117 consecutive patients with advanced OC and 30 women with benign disease who underwent surgery as a control group (CG), was analyzed by the enzyme-linked immunosorbent assay. For statistical analyses, the Chi-square test by Pearson, Fisher's exact test and the Mann-Whitney test were employed.
RESULTS: The concentrations of IL-10 were a median of 9.87 pg/ml (range 7.8 to 500 pg/ml) in the serum and a median of 43.70 pg/ml (range 7.8 to 389.4 pg/ml) in the ascites of the OC patients. The IL-10 level in the sera of the CG was a median of 7.80 pg/ml (range 7.8 to 62.8 pg/ml) and 18.34 pg/ml (range 7.8 to 88.72 pg/ml) in the peritoneal fluid. A significant association was observed between the IL-10 serum levels (p = 0.003) and levels in the peritoneal fluid (p = 0.03) in both OC and the CG. IL-10 was significantly more expressed in the ascites of patients with OC than in their sera (p = 0.003). The concentration of IL-10 correlated significantly with proven conventional prognostic factors such as recurrence status (p = 0.005), volume of (ascites, p < 0.001, serum, p = 0.03), histological grading (p = 0.053) and histological type (ascites p = 0.005/ serum p = 0.09). There was no significant correlation between the levels of lL-10 in the ascites and/or serum and FIGO stage, residual tumor mass or age. The cut-off value of 8.0 pg/ml for IL-10 serum levels had a positive predictive value of 84% (95% CI: 76-91) and a negative predictive value of 29% (95% CI: 16-41), with a specificity and sensibility of 47% (95% CI: 29-65) and 70% (95% CI: 62-78), respectively.
CONCLUSION: Due to the fact that the levels of IL-10 were significantly higher in the ascites and serum of OC patients than in those of the CG, IL-10 may play an important immunosuppressive role in the pathogenesis of OC. The association between high IL-10 levels in ascites and serum and the histological type of the tumor, as well as between the levels in the peritoneal cavity and grading, suggest that IL-10 could be a prognostic factor in OC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617566

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Association of serum cytokines with colorectal polyp number and type in adult males.

Authors:  Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  Eur J Cancer Prev       Date:  2016-05       Impact factor: 2.497

2.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

3.  IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Authors:  Purushottam Lamichhane; Lavakumar Karyampudi; Barath Shreeder; James Krempski; Deborah Bahr; Joshua Daum; Kimberly R Kalli; Ellen L Goode; Matthew S Block; Martin J Cannon; Keith L Knutson
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

4.  Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer.

Authors:  Somayeh Rezaeifard; Mahboobeh Razmkhah; Minoo Robati; Mozhdeh Momtahan; Abbas Ghaderi
Journal:  Iran J Med Sci       Date:  2015-05

5.  Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Claude Laplante; Alex Carignan; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2015-07-01       Impact factor: 4.430

6.  Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations.

Authors:  Mutsa T Madondo; Sandra Tuyaerts; Brit B Turnbull; Anke Vanderstraeten; Holbrook Kohrt; Balasubramanian Narasimhan; Frederic Amant; Michael Quinn; Magdalena Plebanski
Journal:  J Transl Med       Date:  2014-06-23       Impact factor: 5.531

7.  CX3CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancer.

Authors:  Kevin M Hart; Edward J Usherwood; Brent L Berwin
Journal:  Immunol Cell Biol       Date:  2014-03-11       Impact factor: 5.126

8.  IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer.

Authors:  Kevin M Hart; Katelyn T Byrne; Michael J Molloy; Edward M Usherwood; Brent Berwin
Journal:  Front Immunol       Date:  2011-07-21       Impact factor: 7.561

9.  Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.

Authors:  Yuko Tanizaki; Aya Kobayashi; Saori Toujima; Michihisa Shiro; Mika Mizoguchi; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Osamu Takikawa; Kazuhiko Ino
Journal:  Cancer Sci       Date:  2014-06-27       Impact factor: 6.716

Review 10.  Tumor-associated macrophages contribute to tumor progression in ovarian cancer.

Authors:  Emily K Colvin
Journal:  Front Oncol       Date:  2014-06-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.